Phase 2RecruitingAge-related condition
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure (GOAL-HF2)
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of 2 Dose Levels of the Oral Ghrelin Receptor Agonist AC01 Over 12 Weeks in Patients With Chronic Advanced Heart Failure With Reduced Ejection Fraction (HFrEF)
- Sponsor
- AnaCardio AB (Industry)
- Enrollment
- 400 planned
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- AC01; Placebo
- Ages
- adults, older adults
- Registry
- NCT07584967, CTIS2025-524469-25-00
Full record on ClinicalTrials.gov
From the registry
The primary purpose of the study is to evaluate the safety and efficacy of 2 doses of AC01 compared to placebo over 12 weeks in participants with chronic advanced HFrEF.
Primary outcomes
- Absolute Change from Baseline in Composite Echocardiography Z-Score at Week 12
History
Study completion expected
Primary completion expected
Started
Now recruiting
, from Not yet recruiting to Recruiting
Last registry update
Registered